Inhibition of late INa prevents pathological hyperactivation of CaMKIIδ in a murine model of acute Doxorubicin-related cardiocellular toxicity
Abstract
Background: : and Purpose: Doxorubicin (DOX) represents a highly effective anthracycline, whose clinical application is limited by cardiotoxicity. The mechanisms underlying Doxorubicin-induced toxic cardiomyopathy (DICM) involve electrophysiological remodeling with intracellular Na overload as a consequence of increased late I Na , and hyperactivation of CaMKIIδ. Increased [Na] i contributes to CaMKIIδ activation through Na-dependent Ca overload, and CaMKIIδ can further amplify late I Na. Experimental Approach: We tested whether pharmacological inhibition of the late I Na by Ranolazine (RAN, 10 µmol/L) or Empagliflozin (EMPA, 1 µmol/L) is sufficient to attenuate DOX-mediated hyperactivation of CaMKIIδ in isolated wildtype (WT) ventricular cardiomyocytes. The contribution of reciprocal CaMKII-dependent stimulation of late I Na was tested in transgenic S571A cardiomyocytes lacking the CaMKII-specific phosphorylation site S571A on Na V 1.5. Functional readouts were obtained using patch-clamp technique, as well as confocal and epifluorescence microscopy. Key Results: DOX acutely increased late I Na in WT cardiomyocytes by 2-fold, which was associated with redox- and phospho-dependent activation of CaMKIIδ. Hyperactivated CaMKIIδ led to acutely impaired Ca handling as a consequence of diastolic Ca loss from the sarcoplasmic reticulum (SR) mediated by phosphorylation of the RyR2 at the CaMKII-specific phosphorylation site serine-2814. Pharmacological inhibition of late I Na by…
How strong is the evidence?
Evidence Hub reads this as a preprint, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.